Clinical Trial Update: An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease [Phase 1, Phase 2]

View source ↗

Summary

Open-label exploratory study of Fosigotifator in participants with Vanishing White Matter Disease is in Phase 1/Phase 2 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vanishing White Matter Disease

Drugs mentioned

• Fosigotifator (ABBV-CLS-7262)

Snippet

Sponsor: Calico Life Sciences LLC | Conditions: Vanishing White Matter Disease | Phase 1, Phase 2 | Status: RECRUITING